News
Public · Published
Merck gets US FDA emergency use nod for treatment of screwworm in dogs
The US Food and Drug Administration issued an emergency use authorization for Merck's Bravecto tablets to treat New World screwworm in dogs and puppies. The agency said it believes the medicine may work and its potential benefits outweigh its risks when used as authorized; it remains prescription-only.
Published:
Updated:
What happened
The US Food and Drug Administration issued an emergency use authorization for Merck’s Bravecto tablets to treat New World screwworm in dogs and puppies. The agency said it believes the medicine may work and its potential benefits outweigh its risks when used as authorized; it remains prescription-only.
Confirmed
Global impact / market context
The authorization could add sales through veterinary prescriptions, but the transmission to Merck’s revenue depends on how many dogs need treatment. The FDA says most US dogs remain at low risk because confirmed cases are limited to a restricted geographic area.
Analyst inference
This is a limited emergency authorization, not a general approval for all uses: Bravecto is already approved for certain flea and tick uses. Prescription-only access routes treatment through licensed veterinarians, while possible neurological side effects could influence prescribing and demand.
Analyst inference
What to watch
- Watch for FDA updates on the authorization and any changes to its permitted use; the current allowance is for treating screwworm in dogs and puppies. Confirmed
- Veterinarian prescriptions and treatment demand will indicate whether this added use generates meaningful sales for Merck, particularly because most US dogs face low risk. Analyst inference
- Safety reports involving tremors, loss of coordination, or seizures could affect veterinarians’ willingness to prescribe Bravecto and influence treatment choices for infected dogs. Analyst inference
Evidence
- Original source link unavailable